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ABSTRACT 
Objective: The present study was aimed to investigate the effect of salient microneedle (MN) 
geometry parameters like length, density, shape and type on transdermal permeation 
enhancement of Zolmitriptan (ZMT). 
Methods: Two types of MN devices viz. AdminPatch® arrays (ADM) (0.6, 0.9, 1.2 and 
1.5mm lengths) and laboratory fabricated polymeric MNs (PM) of 0.6mm length were 
employed.  In the case of PMs, arrays were applied thrice at different places within a 1.77cm2 
skin area (PM-3) to maintain the MN density closer to 0.6mm ADM. Scaling analyses was 
done using dimensionless parameters like concentration of ZMT (Ct/Cs), thickness (h/L) and 
surface area of the skin (Sa/L2).  
 Results: Micro-injection moulding technique was employed to fabricate PM. Histological 
studies revealed that the PM, owing to their geometry/design, formed wider and deeper 
microconduits when compared to ADM of similar length. Approximately 3.17 and 3.65 fold 
increase in ZMT flux values were observed with 1.5mm ADM and PM-3 applications when 
compared to the passive studies. Good correlations were observed between different 
dimensionless parameters with scaling analyses. Numerical simulations, using MATLAB and 
COMSOL software, based on experimental data and histological images provided 
information regarding the ZMT skin distribution after MN application.  
Discussion: Both from experimental studies and simulations, it was inferred that PM were 
more effective in enhancing the transdermal delivery of ZMT when compared to ADM. 
Conclusion: The study suggests that MN application enhances the ZMT transdermal 
permeation and the geometrical parameters of MNs play an important role in the degree of 
such enhancement. 
 
INTRODUCTION 
Migraine is a chronic, debilitating headache affecting approximately 19% of the population 
globally, with 2-3 times more incidence in women than in men.  It is a neurovascular disorder 
whose pathophysiology is still not clearly understood. An attack/episode of migraine may last 
from 2 to 72 hrs, associated with characteristic symptoms like a pulsating and throbbing 
headache generally on one side of the head, nausea, vomiting, sensitivity to light, etc that 
generally worsens with physical activity. Triptans are 5HT or Serotonin receptor agonists that 
act specifically on migraine. These cause constriction of the dilated cranial blood vessels, 
which is thought to be the cause of migraine1, 2. 
The first among this class of drugs is Sumatriptan, followed by newer ones viz. Zolmitriptan, 
Naratriptan, Rizatriptan, Eletriptan, Almotriptan, Avitriptan and Frovatriptan. Zolmitriptan 
(ZMT) was the second triptan available in the US and many countries, and was developed 
with the goal of creating a more bioavailable, longer half-life, more rapidly absorbed and 
centrally active oral tablet than Sumatriptan2.  ZMT is available as oral tablet, nasal spray and 
oral dispersible tablet formulations, with an optimum dose being 2.5 mg orally, with a 
maximum daily dose of 10 mg/day3.  With all three formulations, the bioavailability is 
between 40-48%.  Nasal sprays of ZMT do offer a pharmacokinetic advantage of a rapid 
absorption across nasal mucosa, which results in a much faster onset of action.  However, the 
overall therapeutic gain or efficacy is not improved significantly when compared to oral 
formulations.  All these formulations of ZMT were reported to have a good chance of 
therapeutic failure with the first dose, requiring a second dose within 2 h to avoid a 
recurrence of the attack within 24 h3,4. 
An ideal delivery system for ZMT must improve the bioavailability and ensure a good 
therapeutic gain within 2 h, i.e., a faster onset of action and a low 24 h recurrence rate when 
compared to existing options, without compromising patient compliance and ease of 
handling.  Transdermal delivery has gained a lot of interest as an alternative to oral and 
parenteral routes, and research is going on extensively to open this route for systemic 
administration of a vast array of drug molecules including large molecules like insulin, 
growth hormone, etc5. 
 
ZMT is a relatively hydrophilic molecule with a log P value of 1.6 and does not have ideal 
properties to permeate through skin and hence a suitable permeation enhancement technique 
should be employed to achieve clinically significant rates of drug permeation. Only a few 
studies have reported on the transdermal delivery of ZMT, using chemical enhancers and 
iontophoresis as permeation enhancement techniques6-8.  Subedi et al., 20117 studied the 
effect of different formulation variables like the specific types of pressure sensitive adhesives 
(PSA), solvent system, permeation enhancers, crystallization inhibitors, etc. on transdermal 
flux of ZMT and reported that permeation enhancers (Polyoxyethylene alkyl ethers) resulted 
in a considerable increase in transdermal flux of ZMT, but induced ZMT crystallization7. Lui 
and Fang, 20158, also developed an adhesive transdermal patch containing ZMT using 
DURO-TAK® 87-4098 (PSA) and 10% Azone as permeation enhancer at a drug load of 4% 
ZMT and reported that 88 ± 51 ng/mL ZMT was detected in systemic circulation within 15 
min of administration of the patches in vivo using rabbit as an animal model, and concluded 
that further optimization can enable effective delivery of ZMT via a transdermal route8. 
Extensive work in the literature emphasizes that microneedles (MN), which are minimally 
invasive systems that can overcome the barrier functions of skin and improve the permeation 
of drug molecules including macromolecules, could be used to effectively enhance the 
permeation of ZMT via a transdermal route9-14.  It was also reported that such enhancement is 
dependent on many aspects of MN design, such as type, shape of MNs, density, materials, 
etc.  There is also an interplay of the effect of these variables and, as such, their effects on the 
permeation of a drug molecule are generally non-intuitive. As a result, their effects are best 
studied for specific case15, 16. 
Consistent with this idea, the present study was designed using a systematic approach to 
investigate the efficiency of MNs in enhancing the transdermal permeation of ZMT and to 
explore the effect of MN geometrical parameters viz. type, MN length, design/shape and 
density on the extent of ZMT transdermal permeation enhancement. Two types of MN 
devices viz. commercially available AdminPatch® arrays (ADM) (0.6, 0.9, 1.2, 1.5 mm 
length) and lab fabricated polymeric MN arrays (PM) (0.6 mm length) of different MN 
densities were employed for the same purpose (Fig. 1). A number of different techniques 
such as etching, lithography and moulding were discussed widely in the literature for the 
manufacture of MNs of different dimensions (100-1800 μm in length), shapes with different 
materials (plastics, silicon, ceramics, metals, etc.). Injection moulding offers several 
advantages in terms of ease of scalability for bulk manufacture, range of materials and good 
reproducibility17.  In this study, micro-injection moulding was employed for fabrication of the 
polymeric MN arrays (PM) using PEEK LT-3 (polyether ether ketone) as reported in Nair et 
al18. 
 
MATERIALS AND METHODS 
Materials  
AdminPatch® MN arrays were purchased from AdminMed, Sunnyvale, U.S.A.  Zolmitriptan 
was obtained from Mylan Laboratories Limited, Hyderabad, India; Sodium chloride, 
isopropyl alcohol, propylene glycol and 1%w/v Safranin solution from Loba Chemie, 
Mumbai, India; Formic acid, acetonitrile, methanol and HPLC water from Merck Specialities 
Pvt. Ltd, Mumbai, India; Haematoxylin and Eosin stain from Sigma-Aldrich, Bengaluru, 
India. All the reagents and chemicals used in the study were of HPLC grade.  Pig ear skin 
was obtained from local abattoirs. 
Fabrication of Polymeric MN (PM) 
MN array components consisted of 25 conical needles, each 0.6 mm in length with a base 
diameter of 0.3 mm, in a 5 x 5 array over a 0.5 x 0.5 cm2  area, supported by a circular 
substrate of diameter 17.5 mm and thickness 0.5 mm. Moulding of these components was 
performed using a Wittmann-Battenfeld Micro-Power 15 micro-injection moulding machine 
as shown in Fig 2A. This machine offers a high repeatability, accurate dosing, clean room 
facility, and robotic component handling which is ideal for the bulk manufacture of MNs.  
The MN mould insert (Fig 2 B) was made out of Stavax ESR (Bohler-Uddeholm Corp, Elgin, 
USA). Sink electrical discharge machining (EDM) was used to create negative MN features 
into the insert and was outsourced to Isometric tool and design Inc. (New Richmond, USA).  
The polymer used for this study is PEEK (Polyetheretherketone) LT-3 grade material, which 
is an FDA-approved semi-crystalline biomaterial manufactured by Invibio Inc, Lancashire, 
UK and is widely employed for medical use. The attractive characteristics of PEEK LT-3 for 
this application include its excellent processability, dimensional stability, mechanical 
strength, chemical resistance and resistance to gamma and ethylene oxide sterilisation 
methods. To ensure the moisture content of the material was suitable for processing, the 
material was dried at a temperature of 150 ºC for 4 hours prior to moulding. 
Moulding trials were performed to optimise the process parameters based on measurement of 
the needle dimensions and substrate flatness.  The optimised parameters for the moulding of 
PM are shown Table 1.  Once the process was stabilised, samples were collected for the 
subsequent experimental work. 
MN dimensional evaluation 
Scanning electron microscope: 
A Hitachi TM-3000 table-top Scanning Electron Microscope was used for analysis of the MN 
insert and needle geometry. The Hitachi TM-300 has a magnification from 15X to 30000X, 
sample chamber of 700 mm diameter and 50 mm thickness. It features 5 kV, 15 kV and 
analysis observation modes. Because of the high aspect ratio and low contrast of the MNs, 
analysis mode was used for imaging.  The major advantage of using TM 3000 SEM was it 
works under low vacuum and does not need specimen coating. 
Confocal laser microscope: 
It is very important to measure the tip radius and height of the MNs and the most common 
methods used are optical or electron microscopy. Because of its steep and complex structures, 
a 3D image analysis gives a better measurement of the needle geometry and quality control. 
In this study an Olympus vertical scanning laser confocal microscope LEXT OLS 4000 was 
used to accurately measure the tip radius and height of MN arrays. 
 
The device offers a broad magnification range from 108X to 17280X and the exact 3D 
reconstruction of the MNs. The confocal laser microscope LEXT scans the surfaces with a 
laser beam with the wavelength of 405 nm thus allowing submicron visualization of material 
and component surfaces with the resolution of down to 0.10 µm. Measurements were taken 
with the 20X lens using the wide range stitching feature with 20 percent overlap to produce a 
measurement area of 5mm x 5mm. A five level brightness switch (Table 2) was enabled to 
accurately illuminate the specimen. 
Atomic force microscope: 
The most important feature of the MN is that the tip has to be sharp in order to effectively 
pierce the skin. So as to confirm the measurements made from confocal laser microscope, 
AFM (MFP-3D Asylum Research Santa Barbara, USA) was used to measure the tip radius of 
the MNs. All AFM scans were made using an MFP-3D scanner from Asylum Research, 
Santa Barbara, USA. Silicon nitride cantilever tips (Applied Nanostructures, Santa Clara, 
USA) with a tip radius of 15 nm and spring constant of 0.3 Nm were used. Images were 
interpreted using integrated MFP-3D™ Igor software (USA). Errors in the piezo-linearity 
were corrected for by using zero and first order flattening. 
 
HPLC method  
RP-HPLC-PDA method was developed specifically for the analysis of ZMT in the 
transdermal permeation samples.  A Shimadzu Prominence HPLC system provided with 
DGU-20A3 degasser, LC-20AD binary pumps, SIL-20AHT auto sampler and SPD-M20A 
PDA detector was used for analysis of the samples.  Data acquisition was carried out using 
LC solutions software.  Separation was achieved on an Agilent Eclipse column (150 × 4.6 
mm; 5 µm).  The mobile phase comprised of 0.02% v/v formic acid : methanol 75:25 (v/v) at 
a flow rate of 1 mL/min with an injection volume of 20 µL and the eluents were monitored at 
221 nm.  The developed method was validated as per ICH guidelines. 
 
Solubility studies  
The solubility of ZMT was studied in different vehicle combinations of propylene glycol 
(PG), polyethylene glycol-400 (PEG), and saline (S) at 70:30, 80:20 and 90:10% v/v ratios.  
To each vehicle system, an excess amount of ZMT was added and vortexed for 1 min in order 
to obtain a saturated solution and the solutions were equilibrated at 37°C in an orbital shaker 
for 24 h.  After equilibration, the samples were centrifuged at 3000 rpm for 10 min and 
filtered through a nylon syringe filter (0.45µm) and all the samples were appropriately diluted 
and analysed by HPLC method. 
Skin Preparation 
Pig ears were collected from the local abattoirs immediately after animals were killed by 
electric current.  The ears were transported to the laboratory in a cooling box without 
previous treatment.  In the laboratory, the pig ears were washed carefully with distilled water 
and the hair was removed from the external part of pig ear using an electrical hair clipper.  
Carefully the full-thickness skin from the external part of the pig ear was separated from 
underlying cartilage using a scalpel and excess fat underlying the skin was removed to a 
thickness of 1.2mm was employed for the in vitro transdermal permeation studies.  The 
dermis side was wiped with isopropyl alcohol to remove the residual adhering fat.  Processed 
skin samples were individually wrapped in plastic bags without air entrapment and stored in a 
deep freezer at -20°C until further use. 
  
Application of MNs on skin samples 
Prior to the in vitro skin permeation experiments, the skin samples were allowed to be 
brought to room temperature and then the skin surface was carefully washed with saline.  
Two types of MN devices viz, ADM (0.6, 0.9, 1.2 and 1.5 mm) and PM (0.6mm) were used 
to poke the skin surface under thumb pressure.   In the case of PM, both single (PM-1) and 
triple (PM-3) insertions at different places within a 1.77cm2 skin area (PM-3) were made in 
order to maintain the MN density closer to ADM of 0.6mm length as shown in Fig 1.  The 
MNs were periodically checked during this process for potential damage using a 
stereomicroscope. 
 
Surface visualization and histological examination of the skin samples  
To visually confirm the disruption of skin layers by the MNs, the arrays were pressed over 
the pig ear skin under thumb pressure and held for 1 min.  Then the skin was stained with 
safranin dye (1% w/v in water) and wiped with isopropanol cotton swabs for the 
identification of the microconduits formed.  In the case of the histological studies, the skin 
section samples with and without MN treatments were prepared after staining with 
haematoxylin and eosin for visualization of skin layers and to display a clear indentation by 
MN penetration.  The sections were observed under a microscope (Olympus; Noida, India).  
The width and depth of microconduits formed were also calculated in triplicate (n = 3 skin 
samples for each MN) with the help of Toup View 3.2 Software (Irwin, U.S.A).  For control, 
skin samples without MN treatment were also prepared. 
 
In Vitro Skin Permeation Studies 
The in vitro transdermal permeation studies were performed using a vertical type Franz 
diffusion cell apparatus fitted with a water circulation system, a water heater and an eight 
stage magnetic stirrer (Orchid Scientifics, Nasik, India). Franz diffusion cells with an 
effective diffusion area of 1.77 cm2 and a receptor volume of around 14 mL were used.  
Saline was used as the receptor fluid.  Pig ear skin was mounted between the donor and 
receptor cells with the SC facing towards the donor cell. The receptor medium was stirred for 
uniform drug distribution at a speed of 600 rpm throughout the experiment.  Care was taken 
to prevent the entrapment of air bubbles at the interface of the skin (dermis) and the receptor 
solution.  The surface of the skin was maintained at 32°C using a circulating water bath.  
After equilibration, 500 µL of donor solutions containing excess amount of ZMT were 
applied on to the skin.  Samples (500 µL) were withdrawn from the receptor fluid at six hour 
increments up to 48 hours and replaced with the fresh saline to maintain a constant volume.  
All the samples were stored at 4°C, prior to the HPLC analysis. 
 
The cumulative permeation profiles were plotted for the cumulative amount of drug 
permeated (nmoL/cm2) as a function of time, for untreated and microneedle treated skin.  The 
flux values and the respective lag times were obtained from the slope and the X-intercept of 
the steady state portion of the cumulative permeation profiles.  Apparent permeability and 
diffusion coefficient values were computed from Fick’s first law of diffusion: 
 
Js is the steady-state flux (nmoL/cm²/hr), M is the cumulative amount of drug permeating the 
skin (nmoL/cm²), A is the area of the skin (1.77 cm2), Kp is the apparent permeability 
coefficient (cm/hr), and ΔC is the difference in concentrations of ZMT in the donor and 
receiver. Sink conditions were maintained in the receiver throughout the experiment and 
hence ΔC was approximated to be the drug concentration in the donor compartment.  
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 Enhancement ratios were also computed to evaluate the relative efficiency of different MNs 
on the ZMT skin permeation enhancement. The enhancement ratios were calculated as 
follows: 
𝐸𝐸𝐸𝐸ℎ𝑎𝑎𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝐸𝐸𝑎𝑎 𝑅𝑅𝑎𝑎𝑎𝑎𝑅𝑅𝑅𝑅 =  Cumulative amount or Flux obtained after MN applicationCumulative amount or Flux obtained from passive studies 
                     
ZMT content in skin 
After the completion of the permeation studies, skin samples were studied for drug 
disposition.  The skin tissue exposed to the donor solution was cut with a scalpel and washed 
with filtered water and blotted with a paper towel in order to remove the drug which adhered 
to the surface.  Then skin was minced with a scalpel, and placed in a pre-weighed vial.   The 
drug was extracted from the skin by equilibrating with 5 mL of acetonitrile at 32°C in an 
orbital shaker.  The solutions were then analyzed by HPLC to determine the ZMT content. 
 
Scaling analyses 
Dimensionless correlations between the amount of ZMT permeated (Ct/Cs) and other 
variables such as the thickness (h/L) and the surface area (Sa/L2) of the skin were made in 
order to gain insights into the overall phenomenon of ZMT transdermal permeation 
enhancement by MN application.  The scaling analyses were carried out based on the 
principles of the Buckingham π theorem where it is defined that the dimensionless 
concentration of a drug, which permeates through skin, can be defined in terms of key non-
dimensional parameters (e.g., MN lengths) using the procedures described in previous 
papers13, 19.  
 
Eq.1 describes the relationship of all the model parameters used for such analyses (Table 3). 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 𝐾𝐾 �𝑆𝑆𝑎𝑎𝐿𝐿4𝐾𝐾𝑒𝑒
𝑉𝑉𝑑𝑑ℎ𝐷𝐷
�
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   (1) 
Where, ‘K’ is a dimensionless constant and ‘n’ is an unknown power; Ct and Cs are the 
amount of ZMT permeated at a given time t (48 h) and the amount of drug loaded in the 
donor compartment for diffusion (surface concentration on skin); Sa is the surface area of 
skin available for diffusion; L is the length of microneedles; Ke and Vd are the first order 
elimination constant and the volume of receptor fluid; ‘h’ is the thickness of skin and D is the 
diffusion coefficient of ZMT in skin. 
Using Eq.1, the correlations between the dimensionless ZMT concentration (Ct/Cs) against 
the dimensionless parameters of the study (h/L and Sa/L2) have been established considering 
that all other variables remain unchanged. 
 
Numerical simulations of experimental studies 
A set of well-defined numerical simulations were carried out in order to gain insights into the 
specific effects of MN shape, dimensions, force of insertion of MN, etc. on the overall 
permeation enhancement of ZMT, and also to obtain the information about ZMT distribution 
within the skin layers during permeation, which are otherwise difficult to obtain directly from 
the experimental data.  The simulations were carried out using MATLAB (Math Works, MA, 
USA) and COMSOL Multiphysics (COMSOL Multiphysics Pvt. Ltd., Stockholm, Sweden) 
programmes. The MATLAB programme was use to process the histological sections images 
of skin treated with MNs and these processed images were further coupled with the 
experimental permeation parameter, e.g., passive diffusion coefficient  and imported into 
COMSOL simulator software13, 20. 
 
Statistical analysis of the data 
Results of the experimental data were subjected to statistical analysis by one way ANOVA 
(using Fischer’s LSD post hoc test) using SYSTAT 13 software (Systat Software Inc., San 
Jose, USA).  Results with a p value of less than 0.05 were considered to have statistically 
significant variance.  Mean of replicate measurements (n = 3) with corresponding standard 
deviation (SD) was used to represent the data and to plot the graphs. 
 
  
RESULTS 
Fabrication and characterization of PM 
The actual dimensions of the PM were determined using 3D Laser Scanning Confocal 
Microscopy (LSCM)   (Fig 3 A), atomic force microscopy (AFM) (Fig. 3 B) and scanning 
electron microscopy (SEM) (Fig 3 C).  The measurement data suggests an average 
microneedle form which was 556 ± 30 µm in height with a tip radius of 32 ± 8 µm, a base 
diameter of 300 µm and MN interspacing of approximately 1 mm at the base. 
 
For better comparison and understanding of the difference in the shape/design between PM 
and ADM devices, 3D confocal images of the 0.6 mm ADM were recorded and are shown in 
Fig 3 D.  Also the difference in base width among the devices can be clearly observed from 
the Fig 1. The various geometry parameters of both types of MN devices are given in Table 
4. 
 
Analytical Method 
A rapid and sensitive HPLC-PDA method was developed for the selective quantification of 
ZMT in transdermal permeation studies.  Under the conditions, ZMT eluted at 2.8 min (Fig 4 
A) with good peak shape.  Also, the specificity of the method to ZMT was demonstrated by 
the UV spectrum and the peak purity index curves (Fig 4 B, C).  The method was validated as 
per ICH guidelines and complied with all the requirements.  
 
Solubility Studies 
Solubility studies for ZMT were performed with a view to select an appropriate donor vehicle 
for conducting in vitro skin permeation studies.  PG:S and PEG:S combinations at 70:30, 
80:20 and 90:10 %v/v were studied for ZMT solubility. Solubility data of ZMT is shown in 
Fig 5. 
 
Surface visualization and histological examination of skin samples 
In order to visually confirm the disruption of skin layers by MN insertion, the arrays were 
pressed over the pig ear skin under thumb pressure and held for 1 min.  Following removal of 
the arrays, the skin samples were stained with safranin (1%w/v). The digital photographs of 
MN treated skin are shown in Fig 6.  
Histological images of skin treated with MNs are shown in Fig 7.  From the images, the 
stratum corneum disruption and the formation of microconduits across skin layers was clearly 
evident. The average penetration depth (vertical)  (n = 3) of the MNs was found to be 180.26 
± 30.39, 302.22 ± 22.28, 400.85 ± 20.83, 478.48 ± 67.72 and 338.20 ± 22.66 µm for ADM 
(0.6, 0.9, 1.2, 1.5 mm) and PM, respectively.  
 
In vitro permeation studies  
The comparative in vitro pig ear skin permeation profiles of ZMT without and with MN 
application were shown in Fig 8.  Various ZMT permeation parameters viz. cumulative 
amount permeated at the end of 48h, steady state flux, lag time, permeability and diffusion 
coefficients without and with microneedle treatment were given in Table 5.   
 
Scaling analyses 
Using scaling analyses, correlations were developed between the dimensionless parameters, 
namely, the amount of ZMT permeated (Ct/Cs) and skin thickness (h/L) and surface area of 
skin (Sa/L2) in order to derive a better understanding on the effect of specific geometry 
parameters of MN, like length (L), on overall permeation enhancement by MNs of same 
design (ADM) (Fig 9A, B ,respectively)13, 19.  Eqs. 2 and 3 describe such relationships among 
the considered parameters within the given range.  These correlations were determined for 
given thickness and surface area of skin while the MN length varies (0.6, 0.9, 1.2 and 1.5 
mm). 
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Good correlation was observed (R2>0.83) between the dimensionless parameters of the study 
(Fig 9). 
Numerical simulations of experimental studies 
The numerical simulations were carried out using the procedures discussed in previous papers 
based on in vitro passive diffusion coefficient values, coupled with histological section 
images (of corresponding MNs)13, 20. Different stages in processing the histological section 
images by MATLAB and COMSOL programs for simulations are shown in Fig 10. The 
numerical simulations were able to provide information regarding the skin distribution of 
ZMT after applying the MNs at any time point and depth (Fig 10D). 
 
DISCUSSION 
The dimensions of the PM were found to be consistent and repeatable with good tip shape, 
confirming the complete filling of the PEEK into the MN insert cavity under the maintained 
processing conditions (Table 1) and the technique used is reliable for the bulk manufacture of 
PMs. Compression tests of PM on a steel plate using Bose Electroforce 3100 instrument with 
a 225 N load cell and Wintest® software (Bose, MN, USA) revealed that the PMs were able 
to withstand compression forces of up to 8 N18.   
A rapid and sensitive HPLC-PDA method was developed for the selective quantification of 
ZMT in transdermal permeation studies. The method complied with all the requirements of 
ICH guidelines and was successfully employed for the quantitative estimation of ZMT in 
various samples throughout the study. 
 
Solubility of ZMT was relatively higher in PG:S when compared with PEG:S combinations 
(p>0.05) (Fig 5). However, a significant difference was not observed among PG:S vehicle 
combinations (p>0.05). PG:S at 70:30%v/v was selected for the ZMT in vitro skin 
permeation studies. 
  
Surface visualization of MN treated skin showed clear distinctions in the number of the 
microconduits formed due to the differences in length and density of MNs in the ADM and 
PM devices (Fig 6). Skin layer disruption and the formation of microconduits was clearly 
evident from histological section images (Fig 7).  The penetration depth about 25-35% of the 
original needle length for ADM and 55-60% for the PM MN. Even though the length of the 
MNs differs in ADM, the percentage of MN penetration is almost same, which is an 
indication of uniformity in thumb pressure under which MNs were applied at different times. 
 
With the ADM devices, as the length of the MNs increased the penetration depth also 
increased. However, the microconduits were found to be wider and deeper with PM when 
compared to ADM of similar lengths i.e. 0.6 mm. These differences in the efficiency of 
creating microconduits in skin layers between the two types of MN devices (ADM and PM) 
may be attributed to the differences in geometry parameters like shape, design and type of 
fabricating material. Regarding the shape/design, the PMs were conical (3D) in shape, and 
the microconduits formed by PM were wider, while the microconduits formed using ADM 
looked merely like a cut on the skin (2D) as the arrays of ADM are low in thickness (2D) 
(Fig 3).  Furthermore, owing to the sturdy and thick base (when compared to ADM) that 
supports the solid PM (Fig 1), the effective resistance (because of the viscoelastic nature) of 
the skin during application of arrays may be less for PM, while the ADM might have 
experienced greater resistance which is because of their thin base and array design21, resulting 
in a relatively shallow penetration with similar MN lengths (0.6 and 0.9 mm ADM). 
 
Significant enhancement in ZMT permeation was observed after the application of MNs into 
the skin (p<0.05) when compared to passive permeation studies (Fig 8). A 1.83, 1.91, 2.35 
and 3.17 fold increase in the cumulative amount (48 h) of ZMT permeated was observed with 
0.6, 0.9, 1.2 and 1.5 mm ADM treatments, respectively, when compared to the passive 
permeation amount.  A similar trend was observed with other permeation parameters like 
permeability and diffusion coefficient values (Table 6).  Significant reduction in the lag time 
was observed after the application of the 1.5 mm ADM when compared to that with the 
passive data and other ADM lengths (p<0.05).   However, there is no statistically significant 
difference between the 0.9 and 1.2mm ADM treatments in terms of lag time (p>0.05). 
 
The ZMT flux values were found to be in the order of 1.5mm > 1.2mm > 0.9mm ≥ 0.6mm > 
passive with ADM treatments.  A 2.26 fold increase in ZMT flux was observed with the 1.5 
mm when compared to passive studies. However, there is no statistically significant 
difference between the 0.6 and 0.9 mm treatments (p>0.05). It was observed that the 
enhancement of ZMT permeation was only marginal with the application of the 0.6 and 0.9 
mm ADM when compared to passive studies (Fig 8). This may be due to the fact that the skin 
disruption/penetration caused by 0.6 and 0.9 mm ADM was less, as supported by the 
histological section images (Fig 7). Moreover, the ZMT permeation was high with the 1.5 
mm ADM when compared to 0.6, 0.9 and 1.2mm even though the density of the MNs is low, 
which is possibly due to longer needle lengths which, in turn, resulted in deeper skin 
penetration. 
 
With the PM application, approximately 1.37 and 3.65 fold increase in the cumulative 
amount (48 h) of ZMT permeated was observed with the PM-1 and PM-3 treatments, 
respectively, when compared to passive permeation amounts.  The lag times were found to be 
significantly lower for PM-3 when compared to passive and PM-1 treatments (p<0.05). The 
ZMT flux values were found to be in the order of PM-3 > PM-1 > passive treatments. A 1.25 
and 2.96 fold increase in ZMT flux was observed with the PM-1 and PM-3, respectively, 
when compared to passive studies. A similar trend was observed with other ZMT permeation 
parameters like permeability and diffusion coefficient values (Table 5) with both the PM 
treatments. 
 
Even though, the skin penetration by PM device (with 0.6mm array) was significantly greater 
when compared to 0.6 and 0.9 mm ADM (Fig 7), the overall permeation enhancement in 
terms of flux, cumulative amount permeated etc. achieved with PM-1 was found to be closer 
to those of 0.6 and 0.9mm ADM (p>0.05).  This may be because the needle density of 0.6 
and 0.9 mm ADM was greater when compared to PM-1 (Table 4), which may have 
compensated the variation in the extent of skin penetration among these MNs, and thus no 
significant variation in overall permeation enhancement was observed among these three 
MNs (p>0.05).  
 
In the case of the PM, a single application of array didn’t cover the 1.77cm2 surface area of 
the skin and hence in order to maintain the MN density closer to the ADM of 0.6mm length, 
the arrays were applied three times at different places within a 1.77cm2 skin area (PM-3) as 
shown in Fig 1.  As the needle density was increased with PM-3, the ZMT transdermal 
permeation increased markedly and was similar to that obtained with 1.5 mm ADM (p>0.05). 
 
Moreover, it is intriguing to note although the needle density of PM-3 (75 MNs) was 
significantly greater when compared to the 1.5 mm ADM (31 MNs), the lag times were found 
to be significantly shorter with 1.5mm ADM (p<0.05), which may be because of deeper 
(vertical) penetration into skin. Even though the depth of the penetration was significantly 
lower with PM when compared to 1.5 mm ADM, the comparable permeation enhancement 
by PM-3 is may be because of higher needle density as stated earlier and wider microconduits 
formed as evidenced by histological section images (Fig 7). 
 
The enhancement in ZMT permeation was found to be in the order of 1.5mm ADM ≥ PM-3 > 
1.2mm ADM > 0.9mm ADM ≥ 0.6mm ADM ≥PM-1 > Passive.  Even though no correlation 
of ZMT skin content was observed with different MN treatments, significantly higher 
amounts of ZMT were found to be distributed in skin layers at the end of 48h with MN 
treated studies and is an indication of potential ZMT skin deposition.  
 
Patel et al., 20096, investigated the effect of iontophoresis on transdermal permeation of 
ZMT both in vitro and in vivo. The cumulative amount of ZMT permeated was found to be 
approximately 263.7 ± 92.7 µg/cm2, in vitro, at the end of 6h with continuous application of 
current (0.25 mA/cm2). However, the preliminary studies carried out in the present 
investigation showed a similar result (cumulative amount permeated) at the end of 48 h with 
1.5mm ADM and PM-3 applications (251.08 ±17.07 and 289.85 ± 64.58 µg/cm2 
respectively). 
Moreover, iontophoresis was reported to be associated with itching, redness and skin 
irritation and tingling sensation, making iontophoresis less patient compliant22.  The MN 
application, especially the poke and patch technique discussed in this investigation, is 
painless and easy to administer when compared to iontophoresis, thus alleviating any issues 
regarding patient compliance. 
Overall, further enhancement in the cumulative amount permeated and other permeation 
parameters like steady state flux of ZMT may be achieved by further optimizing the MN 
geometry, especially of the polymeric MNs (PM) in terms of design, MN length and density, 
and other parameters of the study like drug loading, donor vehicle, formulation, etc. thus 
resulting in more rapid and effective ZMT delivery. 
 
Dimensionless correlations were developed for ADM MNs (same type but differing in 
length) using scaling analyses. Good correlations were observed between the dimensionless 
parameters (Ct/Cs vs h/L and Ct/Cs vs Sa/L2) (Fig 9). These correlations can be used to predict 
the amount of ZMT permeated with high accuracy for other MN lengths in the range of 0.6 - 
1.5mm with similar design as ADM. 
 
From the results of numerical simulations, the flux was represented by white arrows in Fig 
10D showing obvious increment at the upper layers of the skin which is caused by MN 
penetration.  This increment may be extrapolated to a higher drug accumulation rate at the 
blood stream as well as shorter lag time for the diffusion to reach its steady state after the 
application of MNs.  Based on the simulation results, the diffusion profile of ZMT showed 
significant permeation increment with 1.5 mm ADM and PM when compared to other MNs 
in the study.  Furthermore, the advantage of greater penetration by PM can be further 
magnified by increasing the MN density, as in the case of PM-3. 
These simulations can be of great research value as they may be used to predict the degree of 
transdermal permeation enhancement of ZMT with other (new) dimensions and designs of 
MNs using the respective histological section images and the passive diffusion coefficient 
data. 
 
CONCLUSION 
Two types of MN devices (ADM and PM) were employed in this investigation to derive a 
greater understanding on the effects of various geometry parameters specifically on the 
transdermal permeation of ZMT by MN application.  It was observed that the application of 
MNs significantly enhances the transdermal permeation of ZMT across pig ear skin.  In 
addition, the type/shape, density and more importantly, the length of MNs (depth of 
penetration into skin) were found to play a crucial role in the overall permeation enhancement 
of ZMT using this technique.   It may be inferred that the transdermal delivery of ZMT, at 
clinically significant levels and in a painless and non-invasive manner, may by possible using 
MN applications.  This investigation can form a basis for further studies (in vivo) and for 
optimization of various MN parameters to achieve successful delivery of ZMT via. MN 
assisted transdermal delivery systems. 
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 Fig 1. Different MNs used in the study 
  
 Fig 2. (A) Battenfeld micro-power 15 moulding machine; (B) 3D drawing of the 
microneedle insert 
  
 
Fig 3. (A) 3D confocal image of (a) front view of the PEEK MN array (b) Single MN of 
PEEK (c) line measurement of the PM array; (B) SEM image of (a) MN array of PEEK 
(b) top view of the needle (c) Single MN of PEEK; (C) AFM image of the PEEK MN tip 
(b) line graph showing the spherical cap radius of the needle; (D) 3D confocal image of 
0.6 mm ADM showing its design parameters 
  
 Fig 4. A - RIZ Chromatogram; B - UV Spectrum; C - Peak Purity Index 
  
 Fig 5. Solubility Data of ZMT in PG:S and PEG:S Solvent Systems 
  
 Fig 6. Surface images of stained skin without and with MN treatment 
  
 
Fig 7. Penetration depth calculation of ADM and PM in skin (ToupView® screenshot) 
  
 Fig 8. Comparative in vitro skin permeation profiles of ZMT from passive and MN 
treatments.  
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Figure 9. Scaling relationship of different dimensionless groups for permeation of RIZ– 
(A) Effects of dimensionless length of MNs; (B) Effects of dimensionless surface area for 
diffusion 
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 Fig 10. A - The histological section images of skin. B, C - Images treated and processed 
with MATLAB program. D - Images simulated in COMSOL 
 
